14 completed, 6 recruiting, 6 terminated, 1 active not recruiting. 30 Phase 2, 6 Phase 3, 4 Phase 1.
Follow Glomerulonephritis, Membranous: new trials by email Literature Review of Glomerulonephritis, Membranous trials Research Report on Glomerulonephritis, Membranous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial Obinutuzumab - Lupus Nephritis, Membranous Nephropathy | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 65 | 2026-09-02 | 2026-07-23 |
| Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy Rituximab combined with cyclosporine, rituximab - Membranous Nephropathy | Phase 2 / Phase 3 | Recruiting | Peking University First Hospital | 90 | 2026-01-21 | 2026-10-06 |
| Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study Obinutuzumab administration - Membranous Nephropathy - PLA2R Induced | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 20 | 2025-10-01 | 2026-01-06 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis HLX79 10mg/kg/Placebo+HLX01, HLX79 20mg/kg/Placebo + HLX01, HLX79 30mg/kg/placebo+HLX01 - Membranous Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Shanghai Henlius Biotech | 24 | 2025-08-05 | 2025-11-18 |
| Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy Peginterferon Alfa-2A 180 MCG/ML Injectable Solution - Membranous Nephropathy | Phase 2 | Terminated | Centre Hospitalier Universitaire de Nice | 4 | 2023-09-14 | 2026-06-18 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) efgartigimod IV, placebo - Membranous Nephropathy | Phase 2 | Terminated | argenx | 8 | 2023-02-20 | 2024-11-22 |
| Obinutuzumab in Primary MN Obinutuzumab - Membranous Nephropathy | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 20 | 2022-02-18 | 2026-10-05 |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) BCX9930 - Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy | Phase 2 | Terminated | BioCryst Pharmaceuticals | 2 | 2022-02-18 | 2024-05-02 |
| MOR202 for Refractory MN MOR202 - Membranous Nephropathy | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2021-10-22 | 2026-07-13 |
| Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy VB119 - Membranous Nephropathy | Phase 1 / Phase 2 | Terminated | Tenet Medicines | 6 | 2021-05-05 | 2026-02-12 |
| Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome Dalteparin, Apixaban - Nephrotic Syndrome, Thromboembolic Disease | Phase 1 / Phase 2 | Completed | University of Aarhus | 57 | 2021-03-25 | 2025-04-11 |
| Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) MOR202 - Glomerulonephritis, Membranous Nephropathy | Phase 2 | Completed | HI-Bio, A Biogen Company | 24 | 2021-01-20 | 2025-02-07 |
| Belimumab With Rituximab for Primary Membranous Nephropathy Belimumab, Placebo for Belimumab, Rituximab - Membranous Nephropathy, Nephrotic Syndrome | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 58 | 2020-03-06 | 2026-09-18 |
| Personalized Medicine for Membranous Nephropathy Rituximab - Idiopathic Membranous Nephropathy | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 68 | 2020-01-14 | 2025-07-25 |
| Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy LNP023, Rituximab - Idiopathic Membranous Nephropathy | Phase 2 | Terminated | Novartis Pharmaceuticals | 37 | 2019-11-23 | 2024-10-09 |
| Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) MOR202 - Glomerulonephritis, Membranous, antiPLA2R Positive | Phase 1 / Phase 2 | Completed | HI-Bio, A Biogen Company | 31 | 2019-10-15 | 2025-02-24 |
| Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies APL-2 - IgA Nephropathy, Lupus Nephritis | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 21 | 2018-02-26 | 2025-02-13 |
| Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 OMS721 (narsoplimab) - IgAN, LN | Phase 2 | Terminated | Omeros Corporation | 31 | 2016-03-10 | 2026-03-30 |
Showing 20 of 30. Sign in to see all of them.
Lupus Nephritis (6) · Nephrotic Syndrome (6) · Proteinuria (5) · Glomerulonephritis (4) · Glomerulonephritis, IGA (4) · Kidney Diseases (4) · Glomerulonephritis, Membranoproliferative (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1) · Churg-Strauss Syndrome (1) · Glomerulosclerosis, Focal Segmental (1) · Granulomatosis with Polyangiitis (1) · Hyperlipidemias (1) · Hypoalbuminemia (1)
Female Urogenital Diseases (30) · Female Urogenital Diseases and Pregnancy Complications (30) · Immune System Diseases (30) · Male Urogenital Diseases (30) · Nephritis (30) · Urogenital Diseases (30) · Autoimmune Diseases (29) · Urologic Diseases (29) · Glomerulonephritis (26) · Kidney Diseases (26) · Nephrosis (7) · Connective Tissue Diseases (6) · Skin and Connective Tissue Diseases (6) · Lupus Erythematosus, Systemic (5) · Pathological Conditions, Signs and Symptoms (5)
Rituximab (6) · Cyclosporine (4) · belimumab (3) · felzartamab (3) · obinutuzumab (2) · BID protein, human (1) · Dalteparin (1) · Interferon-alpha (1) · Methylprednisolone (1) · N-acetylmannosamine (1) · Prednisone (1) · Sirolimus (1) · Steroids (1) · adrenocorticotropin zinc (1) · apixaban (1)
Radboud University Medical Center (3) · Centre Hospitalier Universitaire de Nice (2) · GlaxoSmithKline (2) · HI-Bio, A Biogen Company (2) · Mario Negri Institute for Pharmacological Research (2) · Mayo Clinic (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Alpine Immune Sciences, Inc. (1) · Apellis Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · BioCryst Pharmaceuticals (1) · National Human Genome Research Institute (NHGRI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1) · Omeros Corporation (1)
United States (12) · France (6) · Netherlands (6) · China (5) · Italy (5) · United Kingdom (5) · Spain (4) · Australia (3) · Germany (3) · South Korea (3) · Canada (2) · Czechia (2) · Taiwan (2) · Argentina (1) · Belgium (1)
Fernando C. Fervenza, M.D., Ph.D. (2) · Anne-Els Van de Logt, M.D., PhD (1) · Carla M Nester, MD, MSA, FASN (1) · Fanfan Hou, MD (1) · Feifei Xu, MD (1) · Fuming Lu, MD (1) · Giuseppe Remuzzi, MD (1) · Howard A Austin, M.D. (1) · Jack F Wetzels, MD (1) · Jack FM Wetzels, M.D.Ph.D. (1)
PMID 34778952, PMID 40465397, PMID 17660026, PMID 25457107, PMID 26087670, PMID 26562836, PMID 31269364, PMID 32231244, PMID 32903623, PMID 33311560, PMID 36821613, PMID 37036696, PMID 39899371, PMID 40478760, PMID 41333097, PMID 41630898, PMID 42027554
2019 (1), 2025 (1)